Jason membrane
Botiss Biomaterials GmbH · Decision date Nov 8, 2026
What did the FDA decide?
FDA recorded a substantially equivalent decision for Jason membrane, a traditional 510(k) submitted by Botiss Biomaterials GmbH of Zossen, Germany. The record lists the device under product code NPL, classification name Barrier, Animal Source, Intraoral, regulation number 872.3930, with Dental as the medical specialty and review panel. The application number and document record identifier are both K260132, received 01/16/2026, with the decision dated 11/08/2026. Substantially equivalent means clearance to market, not premarket approval.
The record does not describe the specific components, materials, or changes distinguishing this submission, nor does it identify a predicate device or summarize the basis for the equivalence finding. Those details would sit in the underlying 510(k) review documents rather than the database entry. No clinical performance, efficacy, or patient-selection information is stated here, and none should be inferred from the clearance alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Nov 8, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260132
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Botiss Biomaterials GmbH
- Product code
- NPL
- Decision code
- SESE
- Decision date
- Nov 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, Animal Source, Intraoral.
- Applicant
- Botiss Biomaterials GmbH
- Product code
- NPL
- FDA device class
- 2
FDA decision timeline
K260132 received
Application receipt date recorded by FDA.
K260132 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NPL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FormaAid Collagen MembraneK260483 | Maxigen Biotech, Inc. | 510(k) clearance | Nov 4, 2026 | FDA |
OSSIX PlusK262415 | Datum Dental, Ltd. | 510(k) clearance | Oct 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Botiss Biomaterials GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Zossen
Sources and methodology
- Original FDA record: K260132
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
